Evolving Management Landscape for Advanced Prostate Cancer

Reactions to treatment advances and new FDA approvals in prostate cancer, and insight regarding the valuable role that precision medicine plays in genitourinary oncology.

EP. 1: Precision Medicine in Advanced Prostate Cancer

August 16th 2021

A panel of physicians who work in the field of genitourinary oncology comment on the evolving role of precision medicine in advanced prostate cancer.

EP. 2: Tissue and Liquid Biopsies in Advanced Prostate Cancer

August 16th 2021

Dr Scott T. Tagawa comments on the pros and cons of liquid and tissue biopsies used to assess patients with advanced prostate cancer.

EP. 3: Phenotypic Biomarkers in Advanced Prostate Cancer

August 23rd 2021

A discussion regarding the use of PSMA PET imaging to detect phenotypic biomarkers that may simplify approaches to precision medicine in advanced prostate cancer.

EP. 4: PSMA-Targeted 18F-DCFPyL PET/CT in High-Risk Prostate Cancer

August 23rd 2021

An interpretation of the OSPREY study of 18F-DCFPyL injection in patients with high-risk prostate cancer and implications of its use.

EP. 5: 18F-DCFPyL PET/CT Imaging for Suspected Recurrent Prostate Cancer

August 30th 2021

A discussion regarding use of the PSMA-targeted 18F-DCFPyL PET/CT to assess patients with suspected recurrence of prostate cancer based on data revealed by the CONDOR trial.

EP. 6: Treatment Advances in mCSPC

August 30th 2021

Treatment Advances in mCSPC

EP. 7: ADT Monotherapy in mCSPC

September 7th 2021

The rationale for treating metastatic castration-sensitive prostate cancer with androgen deprivation therapy as monotherapy as the field advances with newer combination approaches.

EP. 8: Triple Therapy Approaches for mCSPC

September 7th 2021

Potential implications for treating metastatic castration-sensitive prostate cancer with triple therapy based on recently reported data.

EP. 9: mCSPC: Applying New Data into Clinical Practice

September 13th 2021

Recommendations for integrating treatment advances in metastatic castration-sensitive prostate cancer into everyday practice.

EP. 10: Oral GnRH Antagonist Therapy for mCSPC

September 13th 2021

Implications of treating patients with metastatic castration-sensitive prostate cancer with relugolix, an oral GnRH antagonist.

EP. 11: Advances in Nonmetastatic CRPC

September 20th 2021

An overview of drug approvals for nonmetastatic castration-resistant prostate cancer (CRPC), and discussion regarding the potential utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) to guide treatment decisions.

EP. 12: Nonmetastatic CRPC: Treatment Selection

September 20th 2021

An in-depth discussion regarding experience treating nonmetastatic castration-resistant prostate cancer (CRPC) with apalutamide, enzalutamide, and darolutamide, and factors that impact treatment selection.